Current treatments in diabetic macular oedema: Systematic review and meta-analysis

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Ford, John Alexander ^a   Lois, Noemi ^b   Royle, Pamela ^c   Clar, Christine ^d   Shyangdan, Deepson ^c   Waugh, Norman ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d Systematic Reviews   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE;

ADVERSE OUTCOME; ANEMIA; BELL PALSY; BEST CORRECTED VISUAL ACUITY; BLURRED VISION; CATARACT; CENTRAL MACULAR THICKNESS; CEREBROVASCULAR ACCIDENT; CHEST INFECTION; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEAL ABRASION; CORNEAL EPITHELIAL DEFECT; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DISEASE COURSE; DIZZINESS; DRUG CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBASE; ENDOPHTHALMITIS; ERYTHEMA; EYE DISCHARGE; EYE PAIN; EYE SWELLING; FATIGUE; GASTROENTERITIS; GLAUCOMA; HEADACHE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPEREMIA; HYPERTENSION; IMPLANT; INCIDENCE; INTERMITTENT CLAUDICATION; INTRAOCULAR PRESSURE; KERATITIS; LACRIMATION DISORDER; LASER; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; RHEUMATIC POLYMYALGIA; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VOMITING;

EID: 84877683463     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002269     Document Type: Review

References (141)

1. Holman N, Forouhi NG, Goyder E, et al. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: Estimates of total diabetes prevalence for England, 2010-2030. Diabet Med 2011;28:575-82.
2. Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: A systematic review. Eye (London) 2004;18:963-83. (Pubitemid 39430033)
3. Henricsson M, Sellman A, Tyrberg M, et al. Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand 1999;77:218-23. (Pubitemid 29164066)
4. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: Literature review. Curr Med Res Opin 2010;26:1587-97.
5. Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-6.
6. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15. (Pubitemid 28509717)
7. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503.
8. Knudsen LL, Lervang HH, Lundbye-Christensen S, et al. The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema. Br J Ophthalmol 2007;91:1593-5. (Pubitemid 350207378)
9. Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: Retrospective analysis. BMJ 2012;344:e874.
10. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: A systematic review and meta-analysis. Diabetes Care 2009;32:2307-13.
11. Huang ES, Brown SE, Ewigman BG, et al. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478-83. (Pubitemid 47547775)
12. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008;126:1748-54.
13. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol 2012;96:345-9.
14. Happich M, Reitberger U, Breitscheidel L, et al. The economic burden of diabetic retinopathy in Germany in 2002. Graefes Arch Clin Exp Ophthalmol 2008;246:151-9. (Pubitemid 350162696)
15. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
16. Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995;27:48-52.
17. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:2916-24. (Pubitemid 43086714)
18. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-96.
19. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
20. Early Treatment Diabetic Retinopathy Study research group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 1987;94:761-74.
21. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
22. Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features. Retina 2008;28:919-30.
23. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology 2010;117:1078-86.
24. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
25. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic macular oedema-complications and visual outcome. Acta Ophthalmol Scand 2000;78:667-71.
26. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594-602.
27. Nwanze CC, Akinwale A, Adelman RA. Bevacizumab vs. Ranibizumab in preserving or improving vision in patients with wet, age-related macular degeneration: A cost-effectiveness review. Clin Med Insights: Ther 2012;4:29-38.
28. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
29. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35.
30. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26.
31. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9. (Pubitemid 351447960)
32. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8. (Pubitemid 44292310)
33. Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 2011;118:866-72.
34. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six-month outcomes. Ophthalmology 2007;114:2162-7.
35. Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292-9.
36. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405.
37. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-95. (Pubitemid 350211523)
38. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
39. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
40. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-18.
41. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50.
42. Sivaprasad S, Ockrim Z, Massaoutis P, et al. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina 2008;28:1435-42.
43. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-7.
44. Callanan D, Gupta S, Ciulla TA, et al. Efficacy and safety of combination therapy with dexamethasone intravitreal implant (DEX Implant) plus laser photocoagulation versus monotherapy with laser for treatment of diffuse diabetic macular edema (DDME) [abstract]. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 3968.
45. Kim Y, Kang S, Yi CH. Three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2010;51:E-Abstract 4260.
46. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14.
47. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.
48. Ohji M, Ishibashi T Sr, REVEAL study group. Efficacy and safety of ranibizumab 0.5 mg as monotherapy or adjunctive to laser versus laser monotherapy in Asian patients with visual impairment due to diabetic macular edema: 12-month results of the REVEAL Study [abstract]. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 4664.
49. Mitchell P, RESTORE extension study group. 2-Year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): An interim analysis of the RESTORE extension study [abstract]. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 4667.
50. Do DV, Campochiaro PA, Boyer DS, et al. 6 month results of the READ 3 Study: Ranibizumab for edema of the mAcula in diabetes [abstract]. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 5282.
51. Jorge R, Nepomuceno AB, Takaki E, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of refractory diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 347.
52. Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010;30:781-6.
53. Faghihi H, Esfahani MR, Harandi ZA, et al. Intravitreal bevacizumab vs. combination of intravitreal bevacizumab plus macular photocoagulation in clinically significant diabetic macular edema: 6 months results of a randomized clinical trial. Iranian J Ophthalmol 2010;22:21-6.
54. Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012;32:314-21.
55. Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: A randomized clinical trial. Ophthalmologica 2012;227:100-6.
56. Oliveira Neto HL, Andrade RE, Casella M, et al. A randomized clinical trial to compare the efficacy and safety of isolated or combined intravitreal injection of triamcinolone acetonide and bevacizumab for diabetic macular edema ATEMD protocol-a Brazilian clinical trial [abstract]. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 5331.
57. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8. (Pubitemid 43021723)
58. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.
59. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
60. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 Years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32.
61. Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51.
62. Ockrim ZK, Sivaprasad S, Falk S, et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008;92:795-9. (Pubitemid 351839571)
63. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009;127:1566-71.
64. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-9.
65. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison. BMJ 2012;345:e5182.
66. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
67. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388-98.
68. Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: Nested case-control study. BMJ 2012;345:e4203.
69. Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69.
70. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. (Pubitemid 44702055)
71. Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 2011;31:2058-64.
72. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010;33:1523-8.
73. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007;370:1687-97. (Pubitemid 350100775)
74. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-24.
75. PKC-DMES Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30.
76. Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125:469-80. (Pubitemid 46596718)
77. Health Canada. Reports of eye inflammation, endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) following off-label intravitreal use of Avastin (bevacizumab). 2008 [cited 24 Oct 2012]; http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/-2008/avastin-4-hpc-cps-eng.php
78. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
79. Gower EW, Cassard S, Chu L, et al. Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 6644.
80. General Medical Council. Prescribing medicines for use outside the terms of their licence (off-label). 2012 [cited 24 Oct 2012];http://www.gmc-uk.org/ guidance/ethical-guidance/prescriptions-faqs.asp#10
81. U.S.Food and Drug Administration. Off-Label" and investigational use of marketed drugs, biologics, and medical devices-Information Sheet. 2011 [cited 24 Oct 2012];http://www.fda.gov/RegulatoryInformation/Guidances/ ucm126486.htm
82. Alimera Sciences. Alimera Sciences' ILUVIEN Receives Marketing Authorization in France for the Treatment of Chronic Diabetic Macular Edema. 2012 [cited 24 Oct 2012];http://investor. alimerasciences.com/releasedetail.cfm? ReleaseID=692876
83. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye 2008;22:1337-41.
84. National Institute for Health and Clinical Excellence. Ranibizumab for the treatment of diabetic macular oedema:TA237. 2011 [cited 24 Oct 2012];http://publications.nice.org.uk/ranibizumab-for-thetreatment-of-diabetic- macular-oedema-ta237
85. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012;130:972-9.
86. Sivaprasad S, Dorin G. Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Medical Devices 2012;9:189-97.
87. Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol 2010;94:858-63.
88. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-27.
89. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-8.
90. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008;28:420-6. (Pubitemid 351354942)
91. Isaac DL, Abud MB, Frantz KA, et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: A randomized double-blind study. Acta Ophthalmol 2012;90:56-60.
92. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
93. Prager SG, Kriechbaum K, Mylonas G, et al. Comparison of intravitreally applied bevacizumab and triamcinolone on diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2010;51: E-Abstract 4262.
94. Ozturk BT, Kerimoglu H, Bozkurt B, et al. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther 2011;27:373-7.
95. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 2011;5:1011-16.
96. Shahin MM, El-Lakkany RS. A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol 2010;17:250-3.
97. Loftus JV, Sultan MB, Pleil AM, et al. Changes in vision-and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci 2011;52:7498-505.
98. Ferrone PJ, Jonisch J. Ranibizumab dose comparison for the treatment of diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 5333.
99. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638-45.
100. Scott IU, Edwards AR, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
101. Lee SJ, Kim ET, Moon YS. Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Korean J Ophthalmol 2011;25:299-304.
102. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-9.
103. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-30. (Pubitemid 44317541)
104. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
105. Bandello F, Pognuz DR, Pirracchio A, et al. Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2004;242:1024-7. (Pubitemid 40003957)
106. Bonini MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-9. (Pubitemid 44264695)
107. Cellini M, Pazzaglia A, Zamparini E, et al. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 2008;8:5TN.
108. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-63. (Pubitemid 41725412)
109. Chung EJ, Freeman WR, Azen SP, et al. Comparison of combination posterior sub-tenon triamcinolone and modified grid laser treatment with intravitreal triamcinolone treatment in patients with diffuse diabetic macular edema. Yonsei Medi J 2008;49:955-64.
110. Dehghan MH, Ahmadieh H, Ramezani A, et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17. (Pubitemid 351308679)
111. Chew E, Strauber S, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007;114:1190-6.
112. Gil AL, Azevedo MJ, Tomasetto GG, et al. Treatment of diffuse diabetic maculopathy with intravitreal triamcinolone and laser photocoagulation: Randomized clinical trial with morphological and functional evaluation. Arq BrasArquivos Brasileiros de Oftalmol 2011;74:343-7.
113. Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: A randomized clinical trial. Eur J Ophthalmol 2005;15:746-50. (Pubitemid 43074701)
114. Hauser D, Bukelman A, Pokroy R, et al. Intravitreal triamcinolone for diabetic macular edema: Comparison of 1, 2, and 4 mg. Retina 2008;28:825-30.
115. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: A prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-7. (Pubitemid 44051133)
116. Joussen AM, Weiss C, Bauer D, et al. Triamcinolone versus inner-limiting membrane peeling in persistent diabetic macular edema (TIME study): Design issues and implications. Graefes Arch Clin Exp Ophthalmol 2007;245:1781-7. (Pubitemid 350154012)
117. Kaderli B, Avci R. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol 2006;16:718-21. (Pubitemid 44870754)
118. Kang SW, Sa HS, Cho HY, et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124:653-8.
119. Kim JE, Pollack JS, Miller DG, et al. ISIS-DME: A prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-40. (Pubitemid 351655127)
120. Lam DS, Chan CK, Mohamed S, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203. (Pubitemid 46202869)
121. Lee HY, Lee SY, Park JS. Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema. Korean J Ophthalmol 2009;23:153-8.
122. Maia OO Jr, Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: One-year results of a randomized clinical trial. Am J Ophthalmol 2009;147:291-7.
123. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-24. (Pubitemid 38183217)
124. Mohamed S, Leung GM, Chan CK, et al. Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone. Clin Experiment Ophthalmol 2009;37:602-8.
125. Nakamura A, Shimada Y, Horio N, et al. Vitrectomy for diabetic macular edema with posterior subtenon injection of triamcinolone acetonide. [Japanese]. Folia Ophthalmol Japonica 2004;55:958-62. (Pubitemid 40299629)
126. Spandau UH, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003. (Pubitemid 41081412)
127. Tunc M, Onder HI, Kaya M. Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology 2005;112:1086-91. (Pubitemid 40797466)
128. Verma LK, Vivek MB, Kumar A, et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther 2004;20:277-84. (Pubitemid 39108892)
129. Wickremasinghe SS, Rogers SL, Gillies MC, et al. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:4707-11.
130. Yalcinbayir O, Gelisken O, Kaderli B, et al. Intravitreal versus sub-Tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema. Ophthalmologica 2011;225:222-7.
131. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46.
132. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46-51.
133. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17. (Pubitemid 46425557)
134. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-23.
135. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-9.
136. Gillies MC, Islam FM, Zhu M, et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007;91:1323-6. (Pubitemid 47492866)
137. GilliesMC, Simpson JM,GastonC, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabeticmacular edema.Ophthalmology 2009;116:2182-7.
138. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-9. (Pubitemid 39446723)
139. Brown DM, Nguyen QD, Rubio RG, et al. Ranibizumab for Diabetic Macular Edema (DME): 24-Month Efficacy and Safety Results of RISE-a phase 3 randomized controlled trial [abstract]. Invest Ophthalmol Vis Sci 2011;52:E-Abstract 6647.
140. Boyer D, Sy J, Rundle AC, et al. Ranibizumab (Anti-VEGF) for vision loss due to diabetic macular edema-results of two phase III randomized trials [abstract]. 71st Scientific Sessions June 24-28, 2011, San Diego Convention Center-San Diego, California, USA2011;Abstract No, 133-LBOR.
141. Soheilian M, Ramezani A, Yaseri M, et al. Initial macular thickness and response to treatment in diabetic macular edema. Retina 2011;31:1564-73.